Bone Resorption Assay Kit

Cosmo Bio LTD

Catalog No: CSR-BRA-24KIT

Learn more at the Bone Resorption Activity Assay homepage
Click here to browse the Bone-related Products Dashboard
Click here for a well-organized list of Bone, Collagen, and ECM-related products

Background
Useful for the research of skeletal metabolism This product is an assay kit for the measurement of bone resorption activity using a fluoresceinated calcium phosphate-coated plate (patent pending). The coated calcium phosphate is first bound to fluoresceinamine-labeled chondroitin sulfate (FACS), which is released from the calcium phosphate layer into conditioned medium by osteoclastic resorption activity. Bone resorption activity is evaluated by simply measuring the fluorescence intensity of the conditioned medium. This assayprovides a rapid evaluation system unlike that of the traditional pit assay

Features
1) Bone resorption activity is evaluated simply by measuring the fluorescence intensity of the medium.
2) The fluorescence excitation and emission wavelengthsare identical to those for the commonly-used fluorescent dye, FITC
3) Microscopic observation of cell morphology is possible.
4) Pit area analysis is also possible after removing the cells.
Ready to use, sterile components.

References (CSR-BRA-24P、CSR-BRA-48P)
1) Kim JL, Osteogenic activity of yellow flag iris (Iris pseudacorus) extract modulating differentiation of osteoblasts and osteoclasts. Am J Chin Med. 2012, 40(6):1289-305.
2) Wu K, Dextromethorphan inhibits osteoclast differentiation by suppressing RANKLinduced nuclear factor-κB activation. Osteoporos Int. 2013, 24(8):2201-14.
3) Kanzaki H, The keap1/nrf2 protein axis plays a role in osteoclast differentiation by regulating intracellular reactive oxygen species signaling. J Biol Chem. 2013, 288(32):23009-20.
4) Moon SJ, Temporal differential effects of proinflammatory cytokines on osteoclastogenesis. Int J Mol Med. 2013, 31(4):769-77. 5) Fabre C, Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res. 2012, 18(17):4669-81.
6) Harada K, Polyphosphate-Mediated Inhibition of Tartrate-Resistant Acid Phosphatase and Suppression of Bone Resorption of Osteoclasts. PLoS One. 2013, 8(11): e78612 7) Hokugo A, Equilibrium-dependent bisphosphonate interaction with crystalline bone mineral explains anti-resorptive pharmacokinetics and prevalence of osteonecrosis of the jaw in rats. Bone. 2013, 53:59-68.
8) Eda H, A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity. Leukemia. 2014, 28(9):1892- 901 9) Orosa B, Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis. Ann Rheum Dis. 2014, 73(1):298-305 10) Sharma R, Caspase-2 maintains bone homeostasis by inducing apoptosis of oxidatively-damaged osteoclasts. PLoS One. 2014, 9(4):e93696 11) Hsieh CJ, Wedelolactone inhibits breast cancer-induced osteoclastogenesis by decreasing Akt/mTOR signaling. Int J Oncol, 2015, 46(2):555-62. 12) Mishima K, Lansoprazole Upregulates Polyubiquitination of the TNF ReceptorAssociated Factor 6 and Facilitates Runx2-mediated Osteoblastogenesis. EBioMedicine. 2015, 2(12):2046-61
13) Ishikawa S, Inductive Effect of Palmatine on Apoptosis in RAW 264.7 Cells. Evid Based Complement Alternat Med. 2016;2016:7262054 14) Wijekoon S, Chronological differential effects of pro-inflammatory cytokines on RANKL-induced osteoclast differentiation of canine bone marrow-derived macrophages. J Vet Med Sci. 2017, 79(12):2030-2035.
15) Kanzaki H, Nuclear Nrf2 induction by protein transduction attenuates osteoclastogenesis. Free Radic Biol Med. 2014, 77:239-48.
16) Maruyama K, Nociceptors Boost the Resolution of Fungal Osteoinflammation via the TRP Channel-CGRP-Jdp2 Axis. Cell Rep, 2017, 19(13):2730-2742.
17) Wijekoon HMS, Inhibitory effects of sodium pentosan polysulfate on formation and function of osteoclasts derived from canine bone marrow. BMC Vet Res. 2018, 14(1):152. 18) Jin SH, Actin-binding LIM Protein 1 Regulates Receptor Activator of NF-κB LigandMediated Osteoclast Differentiation and Motility. BMB Rep. 2018 Jul;51(7):356-361. 19) Nishida M, S100A12 facilitates osteoclast differentiation from human monocytes. PLoS One. 2018, 13(9):e0204140.
20) Ohnuma K, MicroRNA-124 inhibits TNF-α- and IL-6-induced osteoclastogenesis. Rheumatol Int. 2019, 39(4):689-695.
21) Kumagai M, Fluorinated Kavalactone Inhibited RANKL-Induced Osteoclast Differentiation of RAW264 Cells. Biol Pharm Bull. 2020, 43(5):898-903. 22) Lee EJ, Coumarin Ameliorates Impaired Bone Turnover by Inhibiting the Formation of Advanced Glycation End Products in Diabetic Osteoblasts and Osteoclasts. Biomolecules, 2020, 10(7):1052.
23) Nishioku T, (-)-Epigallocatechin-3-gallate inhibits RANKL-induced osteoclastogenesis via downregulation of NFATc1 and suppression of HO-1-HMGB1- RAGE pathway. Biomed Res. 2020, 41(6):269-277.
24) Park KH, Inhibitory Effect of Rosae Multiflorae Fructus Extracts on the Receptor Activator of NF-κB Ligand-Induced Osteoclastogenesis through Modulation of P38- and Ca 2+-Mediated Nuclear Factor of Activated T-Cells Cytoplasmic 1 Expression. J Bone Metab. 2020, 27(1):53-63.
25) Wada S, Bach1 Inhibition Suppresses Osteoclastogenesis via Reduction of the Signaling via Reactive Oxygen Species by Reinforced Antioxidation. Front Cell Dev Biol, 2020, 8:740.
26) Jeong S, Isoliquiritigenin Derivatives Inhibit RANKL-Induced Osteoclastogenesis by Regulating p38 and NF-κB Activation in RAW 264.7 Cells. Molecules, 2020, 25(17):3908. 27) Lee EJ, Hydroxycoumarin Scopoletin Inhibits Bone Loss through Enhancing Induction of Bone Turnover Markers in a Mouse Model of Type 2 Diabetes. Biomedicines, 2021, 9(6):648. 28) Zhen G, An antibody against Siglec-15 promotes bone formation and fracture healing by increasing TRAP + mononuclear cells and PDGF-BB secretion. Bone Res, 2021, 9(1):47.
29) Cho E, Identification of Novel Genes for Cell Fusion during Osteoclast Formation. Int J Mol Sci, 2022, 23(12):6421. 30) Kelk P, Aggregatibacter actinomycetemcomitans Leukotoxin Activates the NLRP3 Inflammasome and Cell-to-Cell Communication. Pathogens, 2022,11(2):159.
31) Wijekoon S, Pentosan polysulfate regulates hepcidin 1-facilitated formation and function of osteoclast derived from canine bone marrow. PLoS One, 2022, 17(3):e0265596. 32) Okawa H, Mechanism of bisphosphonate-related osteonecrosis of the jaw (BRONJ) revealed by targeted removal of legacy bisphosphonate from jawbone using competing inert hydroxymethylene diphosphonate. eLife. 2022; 11: e76207.
33) Chen Qi, Aberrant activation of TGF-β1 induces high bone turnover via Rho GTPases-mediated cytoskeletal remodeling in Camurati-Engelmann disease. Front Endocrinol (Lausanne). 2022; 13: 913979. 34) Kang IH, Quantitative increase in T regulatory cells enhances bone remodeling in osteogenesis imperfecta. iScience. 2022, 25(9):104818.

Citations for Bone Resorption Assay Kit – 9 Found

Ma et al. 2019. Osthole inhibits osteoclasts formation and bone resorption by regulating NF-κB signaling and NFATc1 activations stimulated by RANKL. J Cell Biochem. :.   , Journal

Kim et al. 2019. Auranofin Inhibits RANKL-Induced Osteoclastogenesis by Suppressing Inhibitors of κB Kinase and Inflammasome-Mediated Interleukin-1β Secretion. Ox Med Cell Longevity. 2019(3503912):.  Journal

Hsu et al. 2019. Sphingosine-1-Phosphate Receptor 2 Controls Podosome Components Induced by RANKL Affecting Osteoclastogenesis and Bone Resorption. Cells. 8(1):E17.   , Journal

Cheng et al. 2016. Myeloid thrombomodulin lectin-like domain inhibits osteoclastogenesis and inflammatory bone loss. Sci Rep. 6:28340.   , Journal

Park et al. 2015. Osteonecrosis of the Jaw Developed in Mice: DISEASE VARIANTS REGULATED BY γδ T CELLS IN ORAL MUCOSAL BARRIER IMMUNITY. J Biol Chem. 290(28):17349-66.   , Journal

Kang et al. 2014. Osteoprotegerin expressed by osteoclasts: an autoregulator of osteoclastogenesis. J Dent Res. 93(11):1116-23.   , Journal

Lee et al. 2014. Potential anti-osteoporotic activity of low-molecular weight hyaluronan by attenuation of osteoclast cell differentiation and function in vitro. Biochem Biophys Res Commun. 449(4):438-43.   , Journal

Kim et al. 2014. Fisetin antagonizes cell fusion, cytoskeletal organization and bone resorption in RANKL-differentiated murine macrophages. J Nutr Biochem. 25(3):295-303.   , Journal

Kuo et al. 2013. Lung tumor-associated dendritic cell-derived resistin promoted cancer progression by increasing Wolf-Hirschhorn syndrome candidate 1/Twist pathway. Carcinogenesis. 34(11):2600-9.   , Journal